Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Glenmark Pharmaceuticals Limited | Goa, India | Makes it and tests it | Problems found, fixed voluntarilyJun 30, 2026 · 7 inspections, 1 with FDA action |
Recalls
- Jan 29, 2025 · Class II · Glenmark Pharmaceuticals Inc., USA
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Lots: Lot Numbers: 19234153, Exp.: 9/2025; 19234900, 19234929, Exp.: 11/2025; 19240936, 19240942, Exp.: 2/2026; 19243199, 19243190, Exp.:7/2026; 19244013, 19244014, Exp.: 9/2026.
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Atomoxetine: every company that makes it
- Form
- capsule, oral
- Strength
- 80 mg
- Approval
- ANDA ANDA079019
- On the market since
- May 30, 2017
- Package NDCs
68462-270-2368462-270-30- Official label
- DailyMed (National Library of Medicine), updated Sep 29, 2026
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?